Leishmaniasis: an update of current pharmacotherapy

Bibliography

• Control of the Leishmaniasis. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases; 22 – 26 March 2010; Geneva. Available from: http://whqlibdoc.who. int/trs/WHO_TRS_949_eng.pdf [Accessed on 29 June 2011]
   Google Scholar
• Magill AJ. Epidemiology of the leishmaniases. Dermatol Clin 1995;13:505-23
   PubMed Web of Science ®Google Scholar
• Pearson RD, Jeronimo SMB, de Queiroz Sousa A. Leishmaniasis. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens and practice. Churchill Livingstone; Philadelphia: 1999. p. 797-813
   Google Scholar
• Zijlstra EE, Musa AM, Khalil EA, Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003;3:87-98
   PubMed Web of Science ®Google Scholar
• Thakur CP, Kumar K. Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes. Ann Trop Med Parasitol 1992;86:355-9
   PubMed Web of Science ®Google Scholar
• Reithinger R, Dujardin JC, Louzir H, Cutaneous leishmaniasis. Lancet Infect Dis 2007;7:581-96
   PubMed Web of Science ®Google Scholar
• Alvar J, Velez ID, Bern C, the WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7(5):e35671
   PubMed Web of Science ®Google Scholar
• Alvar J, Canavate C, Gutierrez-Solar B, Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997;10:298-319
   PubMed Web of Science ®Google Scholar
• Desjeux P, Alvar J. LeishmaniaIHIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003;97:3-15
   PubMed Web of Science ®Google Scholar
• Alvar J, Aparicio P, Aseffa A, The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008;21:334-59
   PubMed Web of Science ®Google Scholar
• Sundar S, More DK, Singh MK, Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000;31:1104-7
   PubMed Web of Science ®Google Scholar
• Rijal S, Chappuis F, Singh R, Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 2003;97:350-4
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, Dejenie A, Assefa Y, A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006;43:357-64
   PubMed Web of Science ®Google Scholar
• Machado PR, Lessa H, Lessa M, Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007;44(6):788-93
   PubMed Web of Science ®Google Scholar
• Sadeghian G, Nilforoushzadeh MA. Effect of combination therapy with systemic Glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006;45:819-21
   PubMed Web of Science ®Google Scholar
• Arevalo I, Tulliano G, Quispe A, Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007;44(12):1549-54
   PubMed Web of Science ®Google Scholar
• Miranda-Verastegui C, Tulliano G, Gyorkos TW, First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis 2009;3:e491
   PubMed Web of Science ®Google Scholar
• Arevalo I, Ward B, Miller R, Successful treatment of drug-resistant cutaneous leishmaniasis in humans by using imiquimod, an immunomodulator. Clin Infect Dis 2001;33:1847-51
   PubMed Web of Science ®Google Scholar
• Firooz A, Khamesipour A, Ghoorchi MH, Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 2006;142:1575-9
   PubMed Web of Science ®Google Scholar
• Thakur CP, Singh RK, Hassan SM, Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 1999;93:9-23
   Google Scholar
• Mishra M, Biswas UK, lha DN, Khan AB. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 1992;340:1256-7
   PubMed Web of Science ®Google Scholar
• Thakur CP, Narain S, Kumar N, Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Ann Trop Med Parasitol 1997;91:611-16
   Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010;362:504-1
   PubMed Web of Science ®Google Scholar
• Bern C, Adler-Moore J, Berenguer J, Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006;43:917-24
   PubMed Web of Science ®Google Scholar
• Gradoni L, Gramiccia M, Scalone A. Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients. Parassitologia 2004;46(1-2):199-201
   PubMedGoogle Scholar
• Syriopoulou V, Daikos GL, Theodoridou M, Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003;36:560-6
   PubMed Web of Science ®Google Scholar
• Davidson RN, di Martino L, Gradoni L, Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996;22:938-43
   PubMed Web of Science ®Google Scholar
• Freire M, Badaro F, Avelar ME, Efficacy and tolerability of liposomal amphotericin B (Ambisome) in the treatment of visceral leishmaniasis in Brazil. Braz J Infect Dis 1997;1(5):230-40
   PubMedGoogle Scholar
• Seaman J, Boer C, Wilkinson R, Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995;21:188-93
   PubMed Web of Science ®Google Scholar
• Moon S, Jambert E, Childs M, von Schoen-Angerer T. A win-win solution?: a critical analysis of tiered pricing to improve access to medicines in developing countries. Globalization and Health 2011;7:39
   PubMed Web of Science ®Google Scholar
• Edwards T, Omollo R, Khalil EA, Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials 2011;12:66
   PubMedGoogle Scholar
• Russo R, Nigro LC, Minniti S, Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996;32:133-7
   PubMed Web of Science ®Google Scholar
• Davidson RN, Di Martino L, Gradoni L, Liposomal amphotericin B (AmBisome) in mediterranean visceral leishmaniasis: a multicentre trial. Q J Med 1994;87:75-81
   PubMedGoogle Scholar
• Montana M, Chochoi N, Monges P, Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of five clinical cases. Pathol Biol 2004;52:66-75
   PubMed Web of Science ®Google Scholar
• Sinha PK, van Griensven J, Pandey K, Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 2011;53(7):e91-8
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, ter Horst R, Chane S, Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 2011;53(12):e152-8
   PubMed Web of Science ®Google Scholar
• Lopez-Velez R, Videla S, Marquez M, Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004;53:540-3
   PubMed Web of Science ®Google Scholar
• Molina I, Falco V, Crespo M, Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2007;60:837-42
   PubMed Web of Science ®Google Scholar
• Solomon M, Baum S, Barzilai A, Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to leishmania braziliensis. J Am Acad Dermatol 2007;56:612-16
   PubMed Web of Science ®Google Scholar
• Solomon M, Pavlotzky F, Barzilai A, Schwartz E. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol 2012; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Solomon M, Pavlotsky F, Leshem E, Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol 2011;25(8):973-7
   PubMed Web of Science ®Google Scholar
• Wortmann G, Zapor M, Ressner R, Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2010;83(5):1028-33
   PubMed Web of Science ®Google Scholar
• Layegh P, Rajabi O, Jafari MR, Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate(Glucantime) in the treatment of cutaneous leishmaniasis. J Parasitol Res 2011;2011:656523
   PubMedGoogle Scholar
• Sundar S, Jha TK, Thakur CP, Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Sinha PK, Sundar S, Phase IV trial of miltefosine in the treatment of Indian visceral leishmaniasis. J Infect Dis 2007;196:591-8
   PubMed Web of Science ®Google Scholar
• Sundar S, Mondal D, Rijal S, Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal–the challenges for diagnosis and treatment. Trop Med Int Health 2008;13:2-5
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh A, Rai M, Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012;55(4):543-50
   PubMed Web of Science ®Google Scholar
• Ramesh V, Katara GK, Verma S, Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. Br J Dermatol 2011;165(2):411-14
   PubMed Web of Science ®Google Scholar
• Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 2005;83:394-5
   PubMed Web of Science ®Google Scholar
• Prajapati VK, Mehrotra S, Gautam S, In vitro antileishmanial drug susceptibility of clinical isolates from patients with indian visceral leishmaniasis–status of newly introduced drugs. Am J Trop Med Hyg 2012; Epub ahead of print
   Google Scholar
• Soto J, Arana BA, Toledo J, Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004;38(9):1266-72
   PubMed Web of Science ®Google Scholar
• Soto J, Rea J, Balderrama M, Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008;78:210-11
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Valda L, Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007;44:350-6
   PubMed Web of Science ®Google Scholar
• Machado PR, Ampuero J, Guimaraes LH, Miltefosine in the treatment of cutaneous leishmaniasis caused by leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010;4(12):e912
   PubMed Web of Science ®Google Scholar
• Jha TK, Olliaro P, Thakur CPN, Randomized controlled trial of aminosidine (paromomycin)vs sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998;316:1200-5
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007;356:2571-81
   PubMed Web of Science ®Google Scholar
• Sinha PK, Jha TK, Thakur CP, Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India. J Trop Med 2011;2011:645203
   PubMedGoogle Scholar
• Hailu A, Musa A, Wasunna M, Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis 2010;4(10):e709
   PubMed Web of Science ®Google Scholar
• Musa AM, Younis B, Fadlalla A, Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis 2010;4(10):e855
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin Pharmacother 2005;6:2821-9
   PubMed Web of Science ®Google Scholar
• el-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by leishmania major. A double blind control study. J Am Acad Dermatol 1992;27:227-31
   PubMed Web of Science ®Google Scholar
• Arana BA, Mendoza CE, Rizzo NR, Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001;65:466-70
   PubMed Web of Science ®Google Scholar
• Krause G, Kroeger A. Topical treatment of American cutaneous leishmaniasis with paromomycin and methylbenzethonium chloride, a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg 1994;88:92-4
   PubMed Web of Science ®Google Scholar
• Soto JM, Toledo JT, Gutierrez P, Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002;66:147-51
   PubMed Web of Science ®Google Scholar
• Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 2009;3(2):e381
   PubMed Web of Science ®Google Scholar
• Jha T, Sundar S, Thakur CP, A phase II dose-rising study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 2005;73(6):1005-11
   PubMed Web of Science ®Google Scholar
• Wassuna M, Felton J, Sabin A, Horton J. A phase II dose-rising study of sitamaquin for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 2005;73(5):871-6
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha PK, Dixon SA, Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India. Am J Trop Med Hyg 84:892-900
   Google Scholar
• Alrajhi AA, Ibrahim EA, De Vol EB, Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002;346:891-5
   PubMed Web of Science ®Google Scholar
• Morizot G, Delgiudice P, Caumes E, Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg 2007;76:48-52
   PubMed Web of Science ®Google Scholar
• Dogra J, Saxena VN. Itraconazole and leishmaniasis: a randomized double-blind trial in cutaneous disease. Int J Parasitol 1996;26:1413-15
   PubMed Web of Science ®Google Scholar
• Momeni AZ, Jalayer T, Emamjomeh M, Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study. Arch Dermatol 1996;132:784-6
   PubMedGoogle Scholar
• Nassiri-Kashani M, Firooz A, Khamesipour A, A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2005;19:80-3
   PubMed Web of Science ®Google Scholar
• Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990;89:147-55
   PubMed Web of Science ®Google Scholar
• Navin TR, Arana BA, Arana FE, Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992;165:528-34
   PubMed Web of Science ®Google Scholar
• Jha SN, Singh NK, Jha TK. Changing response to diamidine compounds in cases of Kala-azar unresponsive to antimonials. J Assoc Phys India 1991;39:314-16
   PubMedGoogle Scholar
• Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 1994;50:107-11
   PubMed Web of Science ®Google Scholar
• Neves LO, Talhari AC, Gadelha EP, A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol 2011;86(6):1092-101
   PubMed Web of Science ®Google Scholar
• Roussel M, Nacher M, Fremont G, Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2006;100(4):307-14
   PubMed Web of Science ®Google Scholar
• Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 2006;50(1):73-9
   PubMed Web of Science ®Google Scholar
• Melaku Y, Collin SM, Keus K, Treatment of kala-azar in Southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30 day sodium stibogluconate monotherapy. Am J Trop Med Hyg 2007;77(1):89
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M, Chakravarty J, New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008;47:1000-6
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha PK, Rai M, Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011;377:477-86
   PubMed Web of Science ®Google Scholar
• Omollo R, Alexander N, Edwards T, Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials 2011;12:166
   PubMed Web of Science ®Google Scholar
• Navin TR, Arana BA, Arana FE, A placebo controlled clinical trial of meglumine antimoniate (Glucantime®) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 1990;42:43-50
   PubMed Web of Science ®Google Scholar
• Velasco-Castrejon O, Walton BC, Rivas-Sanchez B, Treatment of cutaneous leishmaniasis with localized field radio frequency in Tabasco, Mexico. Am J Trop Med Hyg 1997;57:309-12
   PubMed Web of Science ®Google Scholar
• Reithinger R, Mohsen M, Wahid M, Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 2005;40:1148-55
   PubMed Web of Science ®Google Scholar
• Aronson NE, Wortmann GW, Byrne WR, A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous leishmania major infection. PLoS Negl Trop Dis 2010;4(3):e628
   PubMed Web of Science ®Google Scholar
• el Darouti MA, al Rubaie SM. Cutaneous leishmaniasis. Treatment with combined cryotherapy and intralesional stibogluconate injection. Int J Dermatol 1990;29:56-9
   PubMed Web of Science ®Google Scholar
• Asilian A, Sadeghinia A, Faghihi G, The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol 2003;97:493-8
   PubMed Web of Science ®Google Scholar
• Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004;43:281-3
   PubMed Web of Science ®Google Scholar
• Lachaud L, Bourgeois N, Plourde M, Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis 2009;48:e16-22
   PubMed Web of Science ®Google Scholar